Loading
A phase 3 trial of Belantamab mafodotin, Lenalidomide, Dexamethasone in multiple myeloma, run by GlaxoSmithKline, now recruiting.
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) is a phase 3 interventional study registered as NCT06679101 by GlaxoSmithKline, with 520 participants planned, started 2024-12-16 and due to reach its primary completion in 2031-04-28. Interventions recorded: Belantamab mafodotin, Lenalidomide, Dexamethasone, Daratumumab. Conditions listed: Multiple Myeloma, Newly Diagnosed Multiple Myeloma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Newly diagnosed multiple myeloma, transplant-ineligible, Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Lenalidomide.
Shares Belantamab mafodotin, Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, GSK.
Shares Belantamab mafodotin, Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, GSK.
Shares Newly diagnosed multiple myeloma, transplant-ineligible, Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Lenalidomide.
Shares Belantamab mafodotin, Antiemetics for chemotherapy-induced nausea and vomiting, GSK, Lenalidomide.
Shares Newly diagnosed multiple myeloma, transplant-ineligible, Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Lenalidomide.
Shares Belantamab mafodotin, Antiemetics for chemotherapy-induced nausea and vomiting, GSK, Dexamethasone.
Shares Belantamab mafodotin, Antiemetics for chemotherapy-induced nausea and vomiting, GSK, Dexamethasone.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/